RT Journal Article
SR Electronic
T1 The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 294
OP 303
DO 10.2967/jnumed.122.264031
VO 64
IS 2
A1 Anne M. Smith
A1 Nancy A. Obuchowski
A1 Norman L. Foster
A1 Gregory Klein
A1 P. David Mozley
A1 Adriaan A. Lammertsma
A1 Richard L. Wahl
A1 John J. Sunderland
A1 Jean-Luc Vanderheyden
A1 Tammie L.S. Benzinger
A1 Paul E. Kinahan
A1 Dean F. Wong
A1 Eric S. Perlman
A1 Satoshi Minoshima
A1 Dawn Matthews
YR 2023
UL http://jnm.snmjournals.org/content/64/2/294.abstract
AB A standardized approach to acquiring amyloid PET images increases their value as disease and drug response biomarkers. Most 18F PET amyloid brain scans often are assessed only visually (per regulatory labels), with a binary decision indicating the presence or absence of Alzheimer disease amyloid pathology. Minimizing technical variance allows precise, quantitative SUV ratios (SUVRs) for early detection of β-amyloid plaques and allows the effectiveness of antiamyloid treatments to be assessed with serial studies. Methods: The Quantitative Imaging Biomarkers Alliance amyloid PET biomarker committee developed and validated a profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments. Results: On achieving conformance, sites can justify a claim that brain amyloid burden reflected by the SUVR is measurable to a within-subject coefficient of variation of no more than 1.94% when the same radiopharmaceutical, scanner, acquisition, and analysis protocols are used. Conclusion: This overview explains the claim, requirements, barriers, and potential future developments of the profile to achieve precision in clinical and research amyloid PET imaging.